StockNews.com Downgrades Emergent BioSolutions (NYSE:EBS) to Hold

StockNews.com downgraded shares of Emergent BioSolutions (NYSE:EBS) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning.

Other equities research analysts have also issued reports about the company. Rodman & Renshaw reiterated a “buy” rating and set a $16.00 price target on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark raised their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Trading Up 0.9 %

NYSE EBS opened at $9.48 on Wednesday. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. Emergent BioSolutions has a 1-year low of $1.42 and a 1-year high of $15.10. The firm’s fifty day simple moving average is $8.79 and its 200-day simple moving average is $8.22. The company has a market capitalization of $513.63 million, a PE ratio of -2.31 and a beta of 1.57.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Tidal Investments LLC bought a new stake in Emergent BioSolutions during the first quarter worth approximately $34,000. CWM LLC grew its stake in Emergent BioSolutions by 32,706.7% in the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 4,906 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Emergent BioSolutions in the 2nd quarter worth $41,000. Price T Rowe Associates Inc. MD lifted its position in Emergent BioSolutions by 22.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 4,409 shares during the last quarter. Finally, Verus Capital Partners LLC bought a new stake in Emergent BioSolutions during the second quarter valued at about $68,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.